Three new vaccines are being developed against the rare Bundibugyo strain of Ebola virus. The projects are implemented by the American non-profit organization "IAVI".
The most promising is the "IAVI" vaccine, which was created on the basis of the vaccine against the Zairean strain of Ebola. In tests on monkeys, it provided 100 percent protection against infection.
According to the developers, clinical trials with the participation of people can begin within the next 7-9 months, although the researchers are trying to speed up the process. The "IAVI" vaccine is based on a safe virus-carrier, in which proteins of the Ebola virus are incorporated. This allows the immune system to recognize and fight the virus without the risk of infection.
Experts note that there is still no universal vaccine against all types of Ebola virus. Six types of the virus are known to science, only three of which cause disease outbreaks in humans, so a separate vaccine is needed against each.
